[Fe-EOB-tCDTA] generates strong contrast in the blood but not in the liver, despite inhibiting cellular [Gd-EOB-DTPA]2- uptake and partial liver excretion

OBJECTIVE: for liver magnetic resonance imaging (MRI). MATERIALS AND METHODS: . T1 contrast effects in BALB/c mice were evaluated by DCE-MRI. RESULTS: in liver at a clinical dose was significantly higher than that of [Fe-EOB-tCDTA] at both injection doses. CONCLUSION: but without a comparable liver contrast. [Fe-EOB-tCDTA] may serve as an alternative to nonspecific GBCAs, particularly for patients with renal insufficiency and a contraindication to GBCAs. RELEVANCE STATEMENT: This study reports on the synthesis and in vitro and in vivo characterization of the iron complex [Fe-EOB-tCDTA]. This complex demonstrates strong blood contrast and liver excretion, though it lacks strong liver contrast. This complex could serve as an extracellular contrast agent, particularly for patients with reduced kidney clearance. KEY POINTS: [Fe-EOB-tCDTA] was synthesized as a novel iron-based MRI T1 contrast agent with liver excretion. [Fe-EOB-tCDTA] generated a strong blood enhancement effect and exhibited hepatobiliary excretion. Negative charge is crucial to the hepatic uptake and long-lasting liver enhancement.